Alkermes' scientists and business leaders dedicate their unparalleled expertise to delivering pharmaceutical products based on sophisticated drug delivery technologies. Their goal: to enhance therapeutic outcomes in major diseases.
- David A. Broecker, President and Chief Executive Officer
- Kathryn L. Biberstein, Senior Vice President, General Counsel and Secretary, and Chief Compliance Officer
- Madeline D. Coffin, Vice President, Human Resources
- Elliot W. Ehrich, M.D., Senior Vice President, Research and Development, and Chief Medical Officer
- James M. Frates, Senior Vice President, Chief Financial Officer and Treasurer
- Michael J. Landine, Senior Vice President, Corporate Development
- Gordon G. Pugh, Senior Vice President and Chief Operating Officer
David A. Broecker
President and Chief Executive Officer
David Broecker serves as President and Chief Executive Officer for Alkermes. From 2001-2007, David held the position of President and Chief Operating Officer for Alkermes, overseeing all aspects of product research and development, regulatory, quality and manufacturing, business development, and commercialization of products. Prior to joining Alkermes, David held various positions during a 14 year tenure at Eli Lilly and Company where he worked throughout Lilly's worldwide operations including manufacturing, process development, sales, marketing, and business development in both the pharmaceutical division and former medical device division (Guidant Corporation). He is a graduate of Wabash College with a B.A. in chemistry and mathematics. He also holds graduate degrees from the Massachusetts Institute of Technology in chemical engineering and the University of Chicago in business administration. David currently serves on the Advisory Board for the Center for Integrated Behavioral Health Policy at George Washington University.
Kathryn L. Biberstein
Senior Vice President, General Counsel and Secretary, and Chief Compliance Officer
Kathy Biberstein serves as Alkermes' in-house General Counsel. Kathy has held many senior legal positions prior to Alkermes, including General Counsel and Member of the Executive Committee at Serono, Inc. in Geneva, Switzerland, where she built a worldwide legal department. While at Serono, she focused on defending and exploiting the company's worldwide patent estate. Kathy also held positions at Crowell & Moring LLP and the World Economic Forum. She received a B.S. from the General Motors Institute and a J.D. from the University of Michigan Law School.
Madeline D. Coffin
Vice President, Human Resources
Madeline Coffin manages Alkermes' compensation and benefits, staffing, employee relations and employee and organizational development. Madeline has held a number of senior human resource positions at companies including Analog Devices, Inc., Sun Microsystems, Inc., Wang Software, Inc., and Bay Networks, Inc. Prior to joining Alkermes, she founded her own company, which focused on the strategic human resource needs of growing companies for clients ranging from technology to financial services. She holds a B.A. from Penn State University and a Masters of Industrial and Labor Relations from Cornell University.
Elliot W. Ehrich, M.D.
Senior Vice President, Research and Development, and Chief Medical Officer
Elliot Ehrich, M.D., leads the discovery, delivery science, research and development, project management, and medical affairs functions at Alkermes. Prior to joining Alkermes in 2000, Elliot spent seven years at Merck & Co., Inc., overseeing the successful clinical development and registration of novel pharmaceuticals. Elliot is a Fellow of the American College of Rheumatology and has had numerous publications in peer-reviewed journals. Elliot was a Phi Beta Kappa graduate of Princeton University where he received a B.A. in Biochemistry. He worked as research associate at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and later attended Columbia University, College of Physicians and Surgeons where he received an M.D. At Stanford University, Elliot completed a residency in internal medicine and a clinical fellowship in the Department of Immunology and Rheumatology. He was subsequently a postdoctoral research fellow at the Howard Hughes Medical Institute at Stanford University School of Medicine, in the Department of Microbiology and Immunology.
James M. Frates
Senior Vice President, Chief Financial Officer and Treasurer
Jim Frates directs the Finance and Corporate Communications departments at Alkermes. During his tenure, Alkermes has raised substantial public capital and acquired the pulmonary drug delivery company, Advanced Inhalation Research, Inc. (AIR®). Jim was previously a Vice President in charge of the East Coast Life Sciences Practice at Robertson Stephens & Company, Inc. He has also worked in health care investment banking at Morgan Stanley & Company, Inc. and spent a year teaching secondary school at the Royal Shrewsbury School in the U.K., as the Harvard College Fellow. Jim currently serves as Audit Committee Chairman on the Board of Directors of GPC Biotech of Germany and serves as a national chairperson of the Association of Bioscience Financial Officers. Jim received a B.A. in Government from Harvard College and an M.B.A. from Harvard Graduate School of Business Administration.
Michael J. Landine
Senior Vice President, Corporate Development
Mike Landine has led Alkermes' corporate development activities since March 1999. From March 1988 until June 1998, he was Chief Financial Officer and Treasurer of Alkermes. Mike is a member of the Board of Directors of GTC Biotherapeutics, Inc., ECI Biotech, and Kopin Corporation, a developer and manufacturer of compound semiconductor components and miniature flat panel displays for use in wireless and consumer electronic products. Mike received a B.S. in Accounting from Bentley College and is a Certified Public Accountant.
Gordon G. Pugh
Senior Vice President and Chief Operating Officer
Gordon Pugh assumes overall leadership responsibilities for the operations departments at Alkermes, including process development, manufacturing, supply chain management, HSE, information technology, and corporate risk management. Additionally, he oversees site management for both the Cambridge, Massachusetts and Wilmington, Ohio facilities. Gordon has over 25 years of operations and manufacturing experience. Prior to working at Alkermes, Gordon served as Vice President of manufacturing operations in the U.S. and Europe at Lonza Biologics, Inc. Gordon received his B.S. in Microbiology from Cornell University, and his M.B.A. from Northeastern University.